Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bio Key International (BKYI) Shares Outstanding (Weighted Average) (2016 - 2025)

Bio Key International (BKYI) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $6.6 million as the latest value for Q3 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 281.51% to $6.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 million through Sep 2025, up 281.51% year-over-year, with the annual reading at $2.8 million for FY2024, 394.49% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $6.6 million in Q3 2025 for Bio Key International, up from $5.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $8.1 million in Q3 2022 to a low of $260525.0 in Q4 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $3.9 million across 5 years, with a median of $2.8 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): crashed 94.44% in 2021 and later surged 394.49% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $260525.0 in 2021, then grew by 3.89% to $270672.0 in 2022, then surged by 107.0% to $560278.0 in 2023, then soared by 394.49% to $2.8 million in 2024, then skyrocketed by 137.77% to $6.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BKYI at $6.6 million in Q3 2025, $5.8 million in Q2 2025, and $4.7 million in Q1 2025.